We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Positron Emission Tomography Imaging of Brain Amyloid in Normal Pressure Hydrocephalus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01092546
Recruitment Status : Terminated (Changed focus of the program)
First Posted : March 25, 2010
Results First Posted : November 19, 2013
Last Update Posted : December 13, 2013
Sponsor:
Collaborator:
Information provided by (Responsible Party):

Study Description
Brief Summary:
To determine the level of association between the quantitative estimates of brain uptake of [18F]flutemetamol and the quantitative immunohistochemical and histochemistry estimates of amyloid levels in frontal lobe biopsy samples obtained from subjects during shunt placement for NPH.

Condition or disease Intervention/treatment Phase
Normal Pressure Hydrocephalus Drug: [18F]Flutemetamol Phase 3

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: A Principal, Prospective, Open-label Biopsy Study to Validate Detection of Cerebral Cortical Amyloid With Flutemetamol (18F) Injection in Normal Pressure Hydrocephalus (NPH) Subjects.
Study Start Date : March 2010
Primary Completion Date : April 2011
Study Completion Date : April 2011

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Arm 1 Drug: [18F]Flutemetamol
All subjects will receive an IV dose of [18F]flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of [18F]flutemetamol will be 185 MBq.
Other Names:
  • Flutemetamol
  • AH110690


Outcome Measures

Primary Outcome Measures :
  1. Standard Uptake Value Ratio (SUVR) at the Site of the Biopsy Based on the "Cerebellum" (CER) as the Reference Region. [ Time Frame: Post flutemetamol Injection ]
    The level of association between the quantitative estimates of brain uptake of [18F]flutemetamol and the quantitative immunohistochemical estimates of amyloid levels in biopsy samples obtained during shunt placement in patients who have Normal Pressure Hydrocephalus (NPH). The quantitative estimates of brain uptake of [18F]flutemetamol (SUVR) will be made from the analysis of PET images.


Secondary Outcome Measures :
  1. Standard Uptake Value Ratio (SUVR) at the Site of the Biopsy Based on the "Pons" as the Reference Region. [ Time Frame: Post flutemetamol administration ]
    The level of association between SUVR and the quantitative estimates (area percents) of amyloid levels for the following regions: Biopsy site and Contralateral and Composite Regions.


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The subject is at least 50 years of age.
  • The subjects' general health is adequate to comply with study procedures.
  • The subject has been scheduled for a shunt placement procedure for the treatment of NPH.

Exclusion Criteria:

  • The subject has a contraindication for MRI or PET.
  • The subject is pregnant or lactating.
  • The subject has a known or suspected hypersensitivity/allergy to [18F]flutemetamol or to any of the excipients.
  • The subject has participated in any clinical study using an investigational agent within 30 days of dosing.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01092546


Locations
United States, New Jersey
GE Healthcare
Princeton, New Jersey, United States, 08540
Sponsors and Collaborators
GE Healthcare
i3 Statprobe
Investigators
Study Director: Kim A Mansfield, MS GE Healthcare
More Information

Responsible Party: GE Healthcare
ClinicalTrials.gov Identifier: NCT01092546     History of Changes
Other Study ID Numbers: GE-067-009
First Posted: March 25, 2010    Key Record Dates
Results First Posted: November 19, 2013
Last Update Posted: December 13, 2013
Last Verified: November 2013

Keywords provided by GE Healthcare:
Amyloid
Normal pressure hydrocephalus (NPH)
Positron Emission Tomography (PET)
Standard uptake value ratios (SUVR)

Additional relevant MeSH terms:
Hydrocephalus
Hydrocephalus, Normal Pressure
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases